Transcept Pharma refiles Intermezzo NDA
Intermezzo is indicated for the treatment of insomnia or sleeping disorders. The refiling of the application follows a meeting between Transcept and the FDA, to discuss the issues
AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m.